Incidence and clinical background of hepatitis B virus reactivation in multiple myeloma in novel agents’ era
- 30 June 2016
- journal article
- research article
- Published by Springer Nature in Annals of Hematology
- Vol. 95 (9) , 1465-1472
Abstract
There are some reports regarding hepatitis B virus (HBV) reactivation in patients with myeloma who are HBV carriers or who have had a resolved HBV infection, and there is no standard prophylaxis strategy for these patients. We performed a retrospective multicenter study to determine the incidence and characteristics of HBV reactivation in patients with multiple myeloma. We identified 641 patients with multiple myeloma who had been treated using novel agents and/or autologous stem cell transplantation with high-dose chemotherapy between January 2006 and June 2014 at nine Japanese hospitals. The patients’ characteristics, laboratory data, and clinical courses were retrieved and statistically analyzed. During a median follow-up of 101 weeks, one of eight (12.5 %) HBV carriers developed hepatitis and 9 of 99 (9.1 %) patients with resolved HBV infection experienced HBV reactivation; the cumulative incidences of HBV reactivation at 2 years (104 weeks) and 5 years (260 weeks) were 8 and 14 %, respectively. The nine cases of reactivation after resolved HBV infection had received entecavir as preemptive therapy or were carefully observed by monitoring their HBV DNA levels, and none of these cases developed hepatitis. Among patients with multiple myeloma, HBV reactivation was not rare. Therefore, long-term monitoring of HBV DNA levels is needed to prevent hepatitis that is related to HBV reactivation in these patients.Keywords
Funding Information
- Bristol-Myers Squibb Company and MSD K.K.
This publication has 35 references indexed in Scilit:
- Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective studyHepatology, 2013
- Hepatitis B virus reactivation associated with anti‐neoplastic therapyJournal of Gastroenterology and Hepatology, 2012
- Hepatitis B-related events in autologous hematopoietic stem cell transplantation recipientsWorld Journal of Gastroenterology, 2010
- Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancerJournal of Viral Hepatitis, 2009
- High risk of hepatitis B-virus reactivation after hematopoietic cell transplantation in hepatitis B core antibody-positive patientsEuropean Journal of Haematology, 2009
- Chronic hepatitis B: Update 2009 #Hepatology, 2009
- Hepatitis B Virus Reactivation in Lymphoma Patients With Prior Resolved Hepatitis B Undergoing Anticancer Therapy With or Without RituximabJournal of Clinical Oncology, 2009
- Kinetics and Risk of De Novo Hepatitis B Infection in HBsAg–Negative Patients Undergoing Cytotoxic ChemotherapyGastroenterology, 2006
- Lamivudine for the Prevention of Hepatitis B Virus Reactivation in Hepatitis B s-Antigen Seropositive Cancer Patients Undergoing Cytotoxic ChemotherapyJournal of Clinical Oncology, 2004
- Acute Hepatitis B in a Patient with Antibodies to Hepatitis B Surface Antigen Who Was Receiving RituximabNew England Journal of Medicine, 2001